Description
Cagrilintide
Cagrilintide is a synthetic, long-acting amylin analog developed for investigational research. It is designed to interact with amylin receptor pathways involved in appetite signaling, food intake, gastric function, and metabolic regulation. The FDA’s substance database classifies cagrilintide as a peptide and amylin analog.
Researchers continue to study cagrilintide in controlled laboratory and clinical research settings to better understand its receptor activity, pharmacokinetic properties, appetite-related signaling, energy-intake pathways, and broader metabolic effects. Current studies include Phase 3 trials evaluating cagrilintide in people with overweight or obesity, but it remains investigational and is not yet available as an approved prescription medicine.
Research Applications
- Amylin receptor interaction studies
- Appetite and food-intake signaling research
- Metabolic pathway investigation
- Energy-balance research
- Peptide pharmacokinetic studies
- Experimental peptide analysis
Product Specifications
Compound: Cagrilintide
Category: Synthetic Research Peptide
Classification: Amylin Analog Research Peptide
Form: Lyophilized Powder
Purity: Refer to the current Certificate of Analysis
Intended Use: Laboratory research and analytical applications
Research Use Only
This product is supplied exclusively for legitimate laboratory research and analytical purposes. It is intended only for use by qualified professionals in controlled research environments.
Not intended for human or veterinary use, consumption, injection, administration, diagnosis, treatment, weight management, or therapeutic purposes. Cagrilintide remains investigational and has not been approved by the FDA for public medical use.

Reviews
There are no reviews yet.